To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
MSPE Asia in $318m Singaporean take-private
Morgan Stanley Private Equity Asia has offered to de-list Sihuan Pharmaceutical, a Chinese drug maker that specialises in cardio-cerebral vascular drugs.
